Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs ZGN 1061 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zafgen
- 12 Sep 2017 According to a Zafgen media release, interim data is expected in first half of 2018.
- 12 Sep 2017 According to a Zafgen media release, first patient has been dosed.
- 12 Sep 2017 Status changed from not yet recruiting to recruiting, according to a Zafgen media release.